Form 4: Recursion Pharmaceuticals CFO Michael Secora Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Michael Secora, CFO of Recursion Pharmaceuticals, exercised stock options and sold shares of Class A Common Stock under a pre-arranged 10b5-1 trading plan.
Summary
- On July 9 and 10, 2024, Michael Secora, the Chief Financial Officer of Recursion Pharmaceuticals, executed transactions involving the company's Class A Common Stock.
- Secora exercised stock options to acquire 39,375 shares on both days at a price of $2.22 per share.
- Simultaneously, Secora sold 15,000 shares on each day at weighted average prices of $7.3185 and $7.2384, respectively.
- These transactions were conducted under a pre-arranged 10b5-1 trading plan adopted on March 1, 2024.
- Following these transactions, Secora directly owns 1,316,593 shares of Class A Common Stock and holds options to purchase a significant number of additional shares at various exercise prices and vesting schedules.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about stock activity.
Future Outlook
The document does not contain any specific forward-looking statements or guidance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Insider trading activity is a common occurrence in publicly listed companies like Recursion Pharmaceuticals.
- Similar to executives at companies like Amgen or Gilead Sciences, Mr. Secora is utilizing stock options as part of his compensation package.
- The use of 10b5-1 trading plans is a standard practice to avoid accusations of illegal insider trading, mirroring strategies employed by executives at companies such as Pfizer or Johnson & Johnson.
Stakeholder Impact
- Shareholders may be interested in the CFO's transactions as an indicator of management's confidence in the company.
- The transactions have a minor impact on the overall shareholding structure.
Key Dates
| Date | Description |
|---|---|
| 03/01/2024 | Date of adoption of the 10b5-1 trading plan by the Reporting Person |
| 07/09/2024 | Date of first transaction: exercise of stock options and sale of Class A Common Stock |
| 07/10/2024 | Date of second transaction: exercise of stock options and sale of Class A Common Stock |
| 07/11/2024 | Date of signature of the Form 4 filing |
| 02/04/2032 | Expiration date of some stock options |
| 02/01/2033 | Expiration date of some stock options |
| 02/09/2034 | Expiration date of some stock options |
| 03/03/2030 | Expiration date of some stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.